中国中西医结合肾病杂志
中國中西醫結閤腎病雜誌
중국중서의결합신병잡지
CHINESE JOURNAL OF INTEGRATED TRADITIONAL AND WESTERN NEPHROLOGY
2014年
8期
682-685
,共4页
王琴%牟姗%马良%徐维佳%车霞静%曹励欧%方炜%张敏芳%顾乐怡%倪兆慧
王琴%牟姍%馬良%徐維佳%車霞靜%曹勵歐%方煒%張敏芳%顧樂怡%倪兆慧
왕금%모산%마량%서유가%차하정%조려구%방위%장민방%고악이%예조혜
普伐他汀%慢性肾脏病%肾功能%蛋白尿
普伐他汀%慢性腎髒病%腎功能%蛋白尿
보벌타정%만성신장병%신공능%단백뇨
Pravastatin%Chronic kidney disease%Kidney function%Proteinuria
目的：研究普伐他汀对慢性肾脏病患者（CKD）肾功能及尿蛋白的影响，探讨其在 CKD 患者中应用的价值。方法：符合入选标准的48例临床诊断 CKD 的患者，在给与 CKD 常规治疗的基础上随机分组为普伐他汀组（n =25）和对照组（n =23）。普伐他汀组加用普伐他汀20 mg 每晚，维持治疗48周。于治疗前、治疗后4周、12周、24周、36周及48周监测患者血肌酐、血脂、尿蛋白等情况，评估肾小球滤过率。结果：普伐他汀组与对照组在年龄、性别、蛋白尿、肾功能等基线水平的差异无统计学意义。治疗后，普伐他汀组血胆固醇、三酰甘油、低密度脂蛋白均较对照组有所下降，36周后组间达到统计学差异（P ﹤0．05）。普伐他汀组24 h 尿蛋白在治疗8周后与对照组差异存在统计学意义（P ﹤0．05），48周后普伐他汀组尿蛋白较对照组下降52．3%。两组高敏 C 反应蛋白均呈下降趋势，普伐他汀组更为显著。两组估算肾小球率过滤（eGFR）的改变差异无统计学意义。结论：普伐他汀可能可有效改善 CKD 患者的血脂情况，减少蛋白尿，抑制炎症反应，延缓 CKD 进展。
目的：研究普伐他汀對慢性腎髒病患者（CKD）腎功能及尿蛋白的影響，探討其在 CKD 患者中應用的價值。方法：符閤入選標準的48例臨床診斷 CKD 的患者，在給與 CKD 常規治療的基礎上隨機分組為普伐他汀組（n =25）和對照組（n =23）。普伐他汀組加用普伐他汀20 mg 每晚，維持治療48週。于治療前、治療後4週、12週、24週、36週及48週鑑測患者血肌酐、血脂、尿蛋白等情況，評估腎小毬濾過率。結果：普伐他汀組與對照組在年齡、性彆、蛋白尿、腎功能等基線水平的差異無統計學意義。治療後，普伐他汀組血膽固醇、三酰甘油、低密度脂蛋白均較對照組有所下降，36週後組間達到統計學差異（P ﹤0．05）。普伐他汀組24 h 尿蛋白在治療8週後與對照組差異存在統計學意義（P ﹤0．05），48週後普伐他汀組尿蛋白較對照組下降52．3%。兩組高敏 C 反應蛋白均呈下降趨勢，普伐他汀組更為顯著。兩組估算腎小毬率過濾（eGFR）的改變差異無統計學意義。結論：普伐他汀可能可有效改善 CKD 患者的血脂情況，減少蛋白尿，抑製炎癥反應，延緩 CKD 進展。
목적：연구보벌타정대만성신장병환자（CKD）신공능급뇨단백적영향，탐토기재 CKD 환자중응용적개치。방법：부합입선표준적48례림상진단 CKD 적환자，재급여 CKD 상규치료적기출상수궤분조위보벌타정조（n =25）화대조조（n =23）。보벌타정조가용보벌타정20 mg 매만，유지치료48주。우치료전、치료후4주、12주、24주、36주급48주감측환자혈기항、혈지、뇨단백등정황，평고신소구려과솔。결과：보벌타정조여대조조재년령、성별、단백뇨、신공능등기선수평적차이무통계학의의。치료후，보벌타정조혈담고순、삼선감유、저밀도지단백균교대조조유소하강，36주후조간체도통계학차이（P ﹤0．05）。보벌타정조24 h 뇨단백재치료8주후여대조조차이존재통계학의의（P ﹤0．05），48주후보벌타정조뇨단백교대조조하강52．3%。량조고민 C 반응단백균정하강추세，보벌타정조경위현저。량조고산신소구솔과려（eGFR）적개변차이무통계학의의。결론：보벌타정가능가유효개선 CKD 환자적혈지정황，감소단백뇨，억제염증반응，연완 CKD 진전。
Objective:To investigate the effects of pravastatin on kidney function and urinary protein in patients with chronic kidney disease. Methods:48 patients with chronic kidney disease who met the inclusion criteria were randomly divided into the Pravastatin group(n = 25)and Control group(n = 23). The patients from Pravastatin group were given oral pravastatin 20 mg per time,once per day,while the ones from Control group weren’t. The blood lipids,High sensitivity C - reactive protein,24 h urinary protein excretion and renal function expressed by estimated glomerular filtration rate were measured before and(2,4,8,12,24,36, 48week )after the treatment. The incidence of cardiovascular disease was recorded during the 48 - week - following time. Results:No significant change was found in ages,gender and the baseline of proteinuria and renal function between Pravastatin group and Con-trol group. Treated with pravatatin for 36 weeks,Pravatatin group has lower TC,TG,LDL than Control group(P ﹤ 0. 05). There is a significant fall in urinary protein excretion(in 8ed week)and hsCRP in pravatatin - treated patients(P ﹤ 0. 05),and these changes were also significant comparing with the patients in Control group. There were no significant differences in eGFR between these two groups. 2 patients in Pravatatin group and 5 in Control group were recorded with CVD incidence during the 2 - year - following - up (analysed by Kapla - Meier survival curve,chi - square = 4. 015,P ﹤ 0. 05),with no independent factor found. Conclusion:The pavastatin intervention could effectively reduce proteinuria and lipids,ameliorate inflammatory situation,which might slow down the renal function deteriorating progression in patients with CKD stage Ⅲ ~ Ⅴ.
